Collaboration Inquiries
Latest News Press Release Recent Articles Current & Upcoming Meetings and Events Past Meetings and Events
Contact Information
VacciMax® Platform Advantage VacciMax® Proof of Concept VacciMax® Platform Scale-up
Board of Directors Corporate Profile In Memorium Scientific Advisors Senior Management Technical Advisors
Contact Us Partners Press Releases Spayvac Vaccimax Corporate Profile Home
  HOME | PROFILE | VACCIMAX® PLATFORM | PRESS | PARTNERS | CAREERS | CONTACT  


Delivering Breakthrough Vaccines

IVT’s goal is to generate sustainable, long-term revenues by developing and commercializing VacciMax® based vaccines through early clinical development, multiple partnerships and licensing agreements with major vaccine companies.

LATEST NEWS

Vaccine Development Aided by New Techniques

On The Move - ImmunoVaccine Technologis Inc. has been selected as one of Canada's Top 10 Life Sciences Companies

Vaccine breakthrough heralds new cancer treatment

ImmunoVaccine Technologies’ DepoVax™ Shows Positive Results for Cancer and Infectious Diseases

ImmunoVaccine Technologies selected as Canada's Top 10™ Life Sciences Companies

 

SCIENTIFIC ADVISORS TO THE BOARD

 

 

Dr. W. Martin Kast
Chair of the Scientific Advisory Board

Dr. Kast holds a number of prestigious positions including Walter A. Richter Cancer Research Chair, Professor of Molecular Microbiology & Immunology, Director Beckman Center for Immune Monitoring and Co-Leader Tumor-Micro-Environment Program, Norris Comprehensive Cancer Center, USC, Los Angeles, CA.


Dr. Neil Berinstein

Dr. Berinstein obtained his Medical Doctoral Degree at the University of Manitoba and completed training programs at the University of Toronto in Internal Medicine and Medical Oncology and at Stanford University in the area of Immunotherapy for cancer.  Dr. Berinstein was a founding director of the Advanced Therapeutics Program at the Toronto-Sunnybrook Regional Cancer Centre with a long track record in fundamental research and a significant publication record in the area of normal and malignant B cell biology.  Dr. Berinstein became the Program Head of Sanofi Pasteur’s cancer vaccine program in 1998.  He is a Full Professor in the Department of Medicine at the University of Toronto and has recently been nominated as Vice President of the Sabin Institute Cancer Vaccine Consortium. 

 

Dr. Michel Klein

Dr. Klein currently is the Deputy CEO at Etna Biotech s.r.l. and serves as an expert consultant to the EU as a member of the Partnership Board for European and Developing Countries Clinical Trials Partnerships (EDCTP).  Past experience includes Vice President Biotechnology Research - Pasteur Mérieux Connaught Canada, Professor of Immunology - University of Toronto, Corporate Vice President, Science and Technology - Pasteur Mérieux Connaught, Vice President, Science and Technology - Aventis Pasteur Group and Chief Executive Offier, CANVAC - Canadian Network for Vaccines and Immunotherapeutics.

 

Dr. Walter Storkus

Dr. Storkus currently is a Professor (Tenure) with Departments of Dermatology & Immunology at the University of Pittsburgh.  Past positions include Head of Research - Division of Surgical Oncology, Department of Surgery and Professor (Tenure) for Departments for Surgery & Pathology, as well as Departments of Surgery, Dermatology and Immunology at the University of Pittsburgh.  Dr. Storkus has memberships in professional and societies throughout the United States.

 

 

 

 

 

 

 

  HOME | PROFILE | PRODUCT | PRESS | PARTNERS | CAREERS | CONTACT